PKOS Hastalarında Yüksek Kan Basıncı Sıklığı ve Bunun Klinik ve Laboratuvar Parametrelerle İlişkisi

Year 2021, Volume: 10 Issue: 2, 173 - 179, 31.08.2021

Özgür Bulmuş , Akın Usta

https://doi.org/10.53424/balikesirsbd.962549

An Erratum to this article was published on February 28, 2022. https://dergipark.org.tr/en/pub/balikesirsbd/issue/68679/1082975

Abstract

Amaç: Polikistik over sendromlu (PKOS) hastalarda kan basıncı (KB) anormalliklerine sıklıkla rastlanmakla beraber hipertansiyon ve PKOS arasındaki ilişki tam olarak aydınlatılamamıştır. Bu çalışmadaki amacımız ACC/AHA tarafından önerilen yeni sınıflandırmaya göre PKOS’lu hastalarda KB değişikliklerini araştırmaktır. Gereç Yöntem: Çalışmada PKOS tanılı 64 hasta ile aynı yaş grubundaki PKOS olmayan 61 hastanın KB ölçümleri ve bazal karakteristik özellikleri birbiri ile karşılaştırıldı. Bulgular: Kontrol grubuyla karşılaştırıldığında, PKOS hastalarının Ferriman Gallwey skoru (p<0.0001), ortalama diyastolik kan basıncı (p= 0.0099), glukoz (p=0.0049), lökosit (p= 0.0319), nötrofil (p=0.0364) ve Lüteinizan Hormon (LH) (p=0.0018) seviyeleri istatistiksel anlamlı olarak daha yüksek bulundu. PKOS ve Kontrol grubu ACC/AHA klavuzuna göre gruplandırıldığında PKOS hastalarının %59.4’ü anormal KB sahipken kontrol grubundaki hastaların ise %47.5’inde anormal KB tespit edildi. Yapılan istatistik analizde gruplar arasında anlamlı fark tespit edildi (p=0.0343). PKOS hastalarında DKB seviyeleri ile VKİ, serum glukoz seviyesi, HOMA-IR, total kolesterol ve LDL kolesterol arasında pozitif korelasyon tespit edildi. Ayrıca PKOS hastalarında DKB ile HDL kolesterol seviyeleri arasında negatif korelasyon tespit edildi. Sonuç: Üreme dönemindeki PKOS hastalarında KB (özellikle DKB) seviyelerinin insülin direnci, hiperandrojenemi ve dislipideminin varlığıyla ilişkili olarak yükselme eğiliminde olduğu, fakat PKOS ve kontrol grubu arasında hipertansiyon görülme sıklığı açısından fark olmadığı tespit edilmiştir.

Keywords

PKOS, Hipertansiyon, ACC/AHA Guideline Sınıflaması

The Incidance of High Blood Pressure in Women with PCOS and Its Correlation with Clinical and Biochemical Parameters

An Erratum to this article was published on February 28, 2022. https://dergipark.org.tr/en/pub/balikesirsbd/issue/68679/1082975

Abstract

Aim: Although blood pressure abnormalities are frequently encountered in patients with polycystic ovary syndrome (PCOS), the relationship between hypertension and PCOS has not been fully elucidated. Our aim of this study is to investigate BP alteration in patients with PCOS according to the new classification proposed by ACC/AHA guideline. Material and Methods: In this study, we compared the BP measurements and baseline characteristics of 64 patients with PCOS and 61 patients without PCOS in the same age group. Results: Compared with the control group, PCOS patients had increased Ferriman Gallwey score (p<0.0001), mean diastolic blood pressure (p=0.0099), glucose levels (p=0.0049), leukocyte counts (p=0.0319), neutrophil counts (p=0.0364) and LH levels (p=0.0018). When the PCOS and Control patients were classified according to the ACC/AHA guideline, 59.4% of the PCOS patients had abnormal BP, while 47.5% of the patients in the control group had abnormal BP. There was a statistically significant differences between the groups (p=0.0343). The correlation analysis showed that there were positive correlation between DBP levels and BMI, serum glucose level, HOMA-IR, total cholesterol and LDL cholesterol in PCOS patients. In addition, there was a negative correlation between DKB and HDL cholesterol levels in PCOS patients. Conclusion: It has been determined that BP (especially DBP) levels tend to increase in PCOS patients in the reproductive period in relation to the presence of insulin resistance, hyperandrogenemia and dyslipidemia, but there is no difference in the incidence of hypertension between PCOS and control groups.

Keywords

PCOS, Hypertension, ACC/AHA Guideline Classification

References

• Alexander, C.J., Tangchitnob, E.P., & Lepor, N.E. (2009). Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol, 2(4), 232-239.
• Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. (2012). Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod, 27(1), 14-24.
• Azziz, R., Woods, K.S., Reyna, R., Key, T.J., Knochenhauer, E.S., & Yildiz, B.O. (2004). The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab, 89(6), 2745-2749.
• Bentley-Lewis, R., Seely, E., & Dunaif, A. (2011). Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am, 40(2), 433-449.
• Boomsma, C.M., Fauser, B.C., & Macklon, N.S. (2008). Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med, 26(1), 72-84.
• Burghen, G.A., Givens, J.R., & Kitabchi, A.E. (1980). Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab, 50(1), 113-116.
• Carmina, E. (2009). Cardiovascular risk and events in polycystic ovary syndrome. Climacteric, 12 (Suppl 1), 22-25.
• Conway, G.S., Agrawal, R., Betteridge, D.J., & Jacobs, H.S. (1992). Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf), 37(2), 119-125.
• Diamanti-Kandarakis, E., Alexandraki, K., Piperi, C., Aessopos, A., Paterakis T, Katsikis I., & Panidis, D. (2007). Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism, 56(1), 129-134.
• Elting, M.W., Korsen, T.J., Bezemer, P.D., & Schoemaker J. (2001). Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod, 16(3), 556-560.
• Ferriman, D., & Gallwey, J.D. (1961). Clinical assessment of body hair growth in women. J Clin Endocrinol Metab, 21, 1440-1447.
• Guo, X., Zhang, X., Guo, L., Li, Z., Zheng, L., Yu, S., Yang, H., Zhou, X., Zhang, X., Sun, Z., Li, J., Sun, Y. (2013). Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep, 15(6), 703-716.
• Guo, X., Zhang, X., Zheng, L., Guo, L., Li, Z., Yu, S., Yang, H., Zhou, X., Zou, L., Zhang, X., Sun, Z., Li, J., & Sun, Y. (2013). Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoS One, 8(4), e61796.
• Huang, Y., Cai, X., Li, Y., Su, L., Mai, W., Wang, S., Hu, Y., Wu, Y., & Xu, D. (2014). Prehypertension and the risk of stroke: a meta-analysis. Neurology, 82(13), 1153-1161.
• Huang, Y., Cai, X., Liu, C., Zhu, D., Hua, J., Hu, Y., Peng, J., & Xu, D. (2015). Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta-analysis. J Am Heart Assoc, 4(2), e001519.
• Huang, Y., Cai, X., Zhang, J., Mai, W., Wang, S., Hu, Y., Ren, H., & Xu, D. (2014). Prehypertension and incidence of ESRD: a systematic review and meta-analysis. Am J Kidney Dis, 63(1), 76-83.
• Joham, A.E., Boyle, J.A., Zoungas, S., & Teede, H.J. (2015). Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am J Hypertens, 28(7), 847-851.
• Keskin Kurt, R., Okyay, A.G., Hakverdi, A.U., Gungoren, A., Dolapcioglu, K.S., Karateke, A., & Dogan, M.O. (2014). The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. Arch Gynecol Obstet, 290(2), 315-319.
• Laffin, L.J., & Bakris, G.L. (2015). Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol, 21, 20-24.
• Lewington, S., Clarke, R., Qizilbash, N., Peto, R., & Collins, R. (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, 1903-1913.
• Lo, J.C., Feigenbaum, S.L., Yang, J., Pressman, A.R., Selby, J.V., & Go, A.S. (2006). Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab, 91(4), 1357-1363.
• Lord, J.M., Flight, I.H.K., & Norman, R.J. (2003). Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ, 327(7421), 951-953.
• Meyer, C., McGrath, B.P., & Teede, H.J. (2005). Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab, 90(10), 5711-5716.
• Orbetzova, M.M., Shigarminova, R.G., Genchev, G.G., Milcheva, B.A., Lozanov, L.B., Genov, N.S., & Zacharieva, S.Z. (2003). Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome. Folia Med (Plovdiv), 45(3), 21-25.
• Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R, Colao A. (2005). Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab, 90(11), 6072-3076.
• Poulter, N.R., Prabhakaran, D., & Caulfield, M. (2015). Hypertension. Lancet, 386(9995), 801-812.
• Sirmans, S.M., & Pate, K.A. (2014). Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol, 6, 1-13.
• Stein, I.F., & Leventhal, M.L. (1935). Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol, 29(2), 181-191.